Short Summary
The Board instituted the IPR petition against Patent No. 10589225, finding a reasonable likelihood of prevailing on multiple grounds. The institution decision addressed complex issues regarding real party in interest and written description support for genus claims related to flue gas treatment.
Detailed Summary
The Petitioner successfully convinced the Patent Trial and Appeal Board (PTAB) that there was a reasonable likelihood of prevailing on several asserted grounds against Patent No. 10589225, leading to institution. The petition challenged claims using anticipation by Olson-235 (under § 102) and obviousness over Sjostrom/Eckberg and Sjostrom/Olson-646 (under § 103). Crucially, the Board rejected the Patent Owner's argument that the petition was time-barred due to lack of privity in related district court litigation. Furthermore, the Board found insufficient evidence regarding written description support for the genus claims based on the Provisional Application.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in PacifiCorp et al. vs MES, Inc. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
NEURENT MEDICAL INC. et al.vsThe Foundry, LLC et al.
The petitioner asserts that U.S. Patent No. 11,679,077 is invalid due to anticipation and obviousness over multiple prior art references in the field of nasal therapy. The core arguments focus on how Saadat anticipates key claims, while combinations of Makower, Fang, and Edwards-535 render other claims obvious.
PacifiCorp et al.vsMES, Inc.
PacifiCorp and MidAmerican challenge MES’s mercury‑control patent, arguing the Director erred in referring the petition and that the patent’s prosecution contained material misstatements. They seek denial of the patent owner’s Director Review request, emphasizing PTAB efficiency over the MDL.
Advanced Micro Devices, Inc. et al.vsConcurrent Ventures, LLC et al.
AMD and Pensando’s IPR petition against the ’596 patent is challenged by Concurrent Ventures and XtreamEdge, who argue the petition fails to identify claim construction and does not show prior art meets the claimed hardware queue limitations, seeking a discretionary denial of institution.
Neurocrine Biosciences, Inc.vsSpruce Biosciences, Inc.
The PTAB held that Neurocrine Biosciences' challenge succeeded; claims 1‑25 of Spruce Biosciences' ’908 patent were found unpatentable for lack of written description under 35 U.S.C. §112(a). The Board applied Ariad standards and rejected the genus claim.
Advanced Micro Devices, Inc.vsAdvanced Cluster Systems, Inc.
AMD seeks to invalidate 30 claims of its competitor’s ’768 patent, arguing they are obvious over earlier cluster‑computing publications and that discretionary denial is unwarranted.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.